Clinical Trial Update: DP303c in Patients With HER2-positive Advanced Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update for DP303c in HER2-positive advanced breast cancer is not yet recruiting, indicating ongoing evaluation before patient enrollmen…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• DP303c (DP303c)

Snippet

Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Conditions: HER2-positive Advanced Breast Cancer | Phase 3 | Status: NOT_YET_RECRUITING